News from Oasmia Pharmaceutical AB A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 24, 2016, 10:57 ET Oasmia schließt Vereinbarung über Zusammenarbeit bei einem neuen Projekt zur Behandlung von Krebs

Oasmia Pharmaceutical und Karo Pharma haben eine Vereinbarung bezüglich des Krebstherapieprojekts KB9520 von Karo getroffen; dieses Projekt hat...


Apr 27, 2016, 10:00 ET Oasmia Pharmaceutical verkündet positive allgemeine Überlebensergebnisse von der Phase-III-Studie mit Apealea/Paclical für die Behandlung von Eierstockkrebs

Die Daten zur Gesamtüberlebensrate aus der Phase-III-Studie erreichen den primären Endpunkt und belegen, dass die Bevorzugung von...


Apr 27, 2016, 07:00 ET Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive...


Apr 27, 2016, 02:30 ET Oasmia presenterar positiva överlevnadsdata från fas III-studie med Apealea/Paclical för behandling av äggstockscancer

Överlevnadsdata (Overall Survival data) från fas III-studien visade att studiemålet om non-inferiority gällande...


Feb 08, 2016, 14:11 ET Oasmia a déposé une demande d'autorisation de mise sur le marché de son produit phare contre le cancer, Apealea® (Paclical®), auprès de l'Agence européenne des médicaments

Oasmia Pharmaceutical AB (NASDAQ : OASM), a annoncé aujourd'hui avoir déposé une demande d'autorisation de mise sur le...


Feb 08, 2016, 12:12 ET Oasmia presenta una solicitud de autorización de marketing para Apealea®

- Oasmia presenta una solicitud de autorización de marketing a la Agencia Europea del Medicamento para su producto contra el cáncer...


Feb 08, 2016, 11:29 ET Oasmia presenta solicitud de autorización de comercialización ante la Agencia Europea de Medicamentos para su producto líder para el cáncer Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ:OASM) anunció hoy la presentación de una solicitud de autorización de comercialización ante la...


Feb 08, 2016, 11:28 ET Oasmia beantragt Marktzulassung seines führenden Krebsproduktes Apealea® (Paclical®) bei der Europäischen Arzneimittel-Agentur

Oasmia Pharmaceutical AB (NASDAQ: OASM) gab heute bekannt, bei der Europäischen Arzneimittel-Agentur (EMA) einen Antrag auf...


Feb 08, 2016, 09:26 ET Oasmia apresentou um pedido de autorização de marketing à Agência Europeia de Medicamentos para seu produto contra o câncer Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ:OASM) anunciou hoje a apresentação de um pedido de autorização para marketing (MAA) para a...


Feb 08, 2016, 07:00 ET Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

Apealea is a novel formulation of paclitaxel based on the patented excipient platform XR-17, which forms micellar nanoparticles with paclitaxel....


Feb 08, 2016, 02:50 ET Oasmias har ansökt om marknadsföringstillstånd hos den Europeiska läkemedelsmyndigheten (EMA) för cancerläkemedlet Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ: OASM) meddelar idag att en ansökan om marknadsföringstillstånd har skickats till den Europeiska...


Nov 05, 2015, 07:00 ET Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

- Final analysis of the pharmacokinetic study confirms that water soluble and solvent free Paclical and US-market approved Abraxane have nearly...


Oct 30, 2015, 07:00 ET Oasmia Pharmaceutical Receives Order of $7.5 Million in End-user Value for the Russian Market

Oasmia Pharmaceutical AB (NASDAQ: OASM, FWB: OMAX) - a developer of a new generation of drugs within human and veterinary oncology, announced...


Dec 03, 2013, 03:48 ET FDA godkänner Oasmias produktionsanläggning i Uppsala

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...


Dec 03, 2013, 02:45 ET Oasmia meddelar att bolagets tillverkningsenhet i Uppsala har framgångsrikt genomgått FDA-inspektion

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...


Jan 09, 2013, 07:00 ET Oasmia och Abbott tecknar globalt samarbetsavtal för den veterinäronkologiska marknaden

Oasmia och Abbott har ingått ett exklusivt globalt samarbetsavtal beträffande Oasmias två första produktkandidater inom Animal...


Jan 09, 2013, 07:00 ET Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Oasmia and Abbott have entered into an exclusive global collaboration agreement with respect to Oasmia's two leading animal health product...


Jan 07, 2013, 09:25 ET Oasmia Pharmaceutical and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Oasmia and Abbott have entered into an exclusive global collaboration agreement with respect to Oasmia's two leading animal health product...


Jul 15, 2010, 02:59 ET Oasmia Pharmaceutical AB, Sweden - Listing Prospectus: NASDAQ OMX Stockholm

- A Number of Promising New Product Candidates for Cancer Treatment, Within Both Human and Veterinary Oncology ABOUT OASMIA Oasmia is developing...


Apr 14, 2009, 08:02 ET Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA

Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer....